Jack Arbiser, MD, PhD, principal investigator and professor of dermatology at Emory University School of Medicine, has identified a new compound as an effective treatment for rosacea. Canfield’s VISIA Skin Analysis was used in clinical trials to document decreases in redness and track responses to the novel topical treatment, ACU-D1 (Accuitis Inc.). 

“The advantage of using Canfield imaging is that it is not subjective and operative dependent like the other measures we use [for] rosacea. With Canfield imaging, we were able to assess responses both qualitatively and quantitatively.”

The study authors also credited the standardization of Canfield’s imaging system with making the study, “less susceptible to investigator bias” and predicted, “the imaging is likely to be used as an objective measure in the future to gauge the effectiveness of rosacea treatments.” 

To read the article in full click here. To read the published results in the Journey of Drugs in Dermatology, click here.